论文部分内容阅读
目的比较布地奈德福莫特罗单独治疗与孟鲁司特钠联合布地奈德福莫特罗治疗中重度哮喘的疗效。方法选取中重度哮喘患者66人随机分为两组,布地奈德福莫特罗治疗组(单药组,例数=33)和孟鲁司特钠联合布地奈德福莫特罗治疗组(联合组,例数=33),分别记录2组治疗前、治疗3个月后日间、夜间症状评分,治疗前后一秒钟用力呼气量/用力肺活量(FEV1/FVC%)、嗜酸性粒细胞(EOS)计数。结果联合治疗和单药治疗后哮喘症状评分、EOS计数均较明显低于治疗前,联合组症状改善优于单药组(P<0.05)。2组治疗后FEV1/FVC%均明显上升(P<0.05),联合组较单药组上升更明显(P<0.05)。结论孟鲁司特钠与布地奈德福莫特罗联合治疗中重度哮喘,在消除气道炎症反应中起协同作用。
Objective To compare the efficacy of budesonide formoterol monotherapy with montelukast combined with budesonide formoterol in the treatment of moderate-to-severe asthma. Methods Sixty-six patients with moderate-severe asthma were randomly divided into two groups: budesonide formoterol treatment group (single drug group, n = 33) and montelukast sodium combined with budesonide formoterol treatment group Combined group, the number of cases = 33), were recorded before treatment, respectively, two months after treatment, three months after treatment, nighttime symptom score, forced expiratory volume / forced vital capacity (FEV1 / FVC% Cell (EOS) count. Results The asthma symptom score and EOS count after combined treatment and monotherapy were significantly lower than those before treatment, and the symptoms in combination group were better than those in monotherapy group (P <0.05). The FEV1 / FVC% of the two groups were significantly increased after treatment (P <0.05), and the combination group was more obvious than the single drug group (P <0.05). Conclusion Montelukast combined with budesonide formoterol in the treatment of moderate-severe asthma, play a synergistic role in the elimination of airway inflammation.